Clarivate Plc, a global leader in providing trusted information and insights to accelerate the pace of innovation, has announced the launch of its Coronavirus, Virology, and Infectious Disease (CVID) Data Lake to support global researchers and policy makers in their efforts to make data-driven decisions that accelerate disease response, prevent and prepare for future pandemics.
The CVID Data Lake is the first of several therapeutically-oriented data lakes from Clarivate, bringing together the comprehensive information and insights that power the company’s market-leading tools, analytics and services, including real-world data (RWD) from DRG; scientific, clinical, regulatory and commercial data from CortellisTM; cited scholarly references indexed in Web of ScienceTM; and both content and data from award-winning news service, BioWorldTM, in one centralised source. Data from other sources can also be integrated, further enhancing derived insights.
During these unprecedented times, researchers and policy makers need to connect the dots across multiple data points. Collaboration across public and private networks is integral to solving the current health crises and preventing future ones. The CVID Data Lake is a uniquely unified dataset focused on the coronaviruses, including COVID-19, as well as virology, super viruses and infectious diseases, enabling researchers to mine and interrogate harmonised data from a single, expertly curated source and access complete, structured and connected data to enable fact and evidence-based decisions.
Now, more than ever, pharma and biotech companies are interested in understanding the disease impact on clinical trials and treatment patterns, monitoring how research funding and the regulatory landscape is evolving in response to COVID-19, optimising the use of biomedical R&D and manufacturing resources, and developing global strategies to support pricing, market access and reimbursement in areas of interest.
Government agencies are looking to measure the impact of infectious disease on the capacity of the healthcare system and essential supplies, analyse how the health policy, research and regulatory landscape is changing in response to COVID-19, and develop pricing and reimbursement policies to ensure access to medicines. The insights derived from the CVID Data Lake support these use cases and more – providing unprecedented decision support and planning inputs while serving as a bridge between policy and practice and enabling improved use of resources across the public-private continuum.
The CVID Data Lake features all related content in one place, connected in new ways, supporting a multitude of end users, to enable deeper insights and delivery of complex and high value use cases. Clients can choose from an array of delivery options depending on their resource needs and expertise, including: datasets and programmatic access; preconfigured dashboards, reports or customised tools; custom analytics based on specific requirements; or consulting engagements that include analysis and recommendations.
The CVID Data Lake includes: real-world patient data; drug pipeline data; genes and targets; clinical trials; digital health data; publication and citation data; epidemiology; regulatory intelligence; patents and more. Other therapy areas will be launched to help researchers accelerate innovation in other therapeutic areas. The new offering further demonstrates how the combined expertise, data and technologies of Clarivate and DRG, which was acquired by Clarivate earlier this year, can support customers across the entire drug, device and medical technology lifecycles.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
Click here to read the original press release.
